| Market Cap | 259.19M | P/E | - | EPS this Y | -94.40% | Ern Qtrly Grth | - |
| Income | -114.96M | Forward P/E | -1.50 | EPS next Y | -3.20% | 50D Avg Chg | -12.00% |
| Sales | 154.06M | PEG | 0.08 | EPS past 5Y | - | 200D Avg Chg | -28.00% |
| Dividend | N/A | Price/Book | 1.39 | EPS next 5Y | -16.40% | 52W High Chg | -51.00% |
| Recommedations | 1.70 | Quick Ratio | 4.33 | Shares Outstanding | 81.79M | 52W Low Chg | 5.00% |
| Insider Own | 0.92% | ROA | -17.01% | Shares Float | 60.39M | Beta | 1.22 |
| Inst Own | 72.83% | ROE | -81.12% | Shares Shorted/Prior | 3.70M/2.29M | Price | 4.29 |
| Gross Margin | -28.46% | Profit Margin | -74.62% | Avg. Volume | 473,401 | Target Price | 12.30 |
| Oper. Margin | -435.05% | Earnings Date | Aug 8 | Volume | 258,401 | Change | -3.60% |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Oppenheimer | Outperform | May 15, 24 |
| Wedbush | Outperform | May 14, 24 |
| HC Wainwright & Co. | Buy | May 14, 24 |
| B of A Securities | Buy | May 8, 24 |
| Piper Sandler | Overweight | Apr 3, 24 |
| Oppenheimer | Outperform | Apr 3, 24 |
| Truist Securities | Buy | Apr 3, 24 |
| JMP Securities | Market Outperform | Apr 3, 24 |
| Oppenheimer | Outperform | Mar 28, 24 |